You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Eisai and Biogen present promising lecanemab study results

Eisai and Biogen have announced the results from Eisai’s global phase 3 confirmatory Clarity Alzheimer’s disease (AD) clinical study of lecanemab. Results were presented at the 2022 Clinical Trials on Alzheimer’s Disease conference.